Kits
Biologic therapy monitoring: IDKmonitor® Infliximab total ADA, ELISA
Kits
Description
Chronic inflammatory diseases like Crohn’s disease, ulcerative colitis or rheumatoid
arthritis are often treated with anti-TNFα antibodies which target directly the underlying
inflammatory processes.
The clinical efficacy of an anti-TNFα therapy correlates with the trough level of the
therapeutic antibody, the drug level just before the next application of the anti-TNFα
antibody [1–3]. Several factors influence the trough level, among them dosage and
frequency of anti-TNFα blocker infusion, disease activity, individual pharmacokinetics
and immune reaction (formation of anti-drug antibodies, ADA). It is thought that
ADA functionally neutralise the therapeutic antibodies or induce their rapid elimination
[4]. Consequences of ADA formation can be therapy failure and allergic reactions
during anti-TNFα antibody application [1, 5].
The IDKmonitor® Infliximab total ADA ELISA for the detection of total antibodies
against infliximab (e.g. REMICADE®) measures free and bound antibodies against
infliximab. This assay allows a reliable determination of ADA even in the presence of
infliximab; therefore it is ideal for therapy monitoring when a measurable infliximab
concentration is expected, for example shortly after the last infusion. In combination
with the drug level determination, the IDKmonitor® Infliximab total ADA ELISA is an
opportunity for the treating physician to monitor and optimise the therapy early on.
arthritis are often treated with anti-TNFα antibodies which target directly the underlying
inflammatory processes.
The clinical efficacy of an anti-TNFα therapy correlates with the trough level of the
therapeutic antibody, the drug level just before the next application of the anti-TNFα
antibody [1–3]. Several factors influence the trough level, among them dosage and
frequency of anti-TNFα blocker infusion, disease activity, individual pharmacokinetics
and immune reaction (formation of anti-drug antibodies, ADA). It is thought that
ADA functionally neutralise the therapeutic antibodies or induce their rapid elimination
[4]. Consequences of ADA formation can be therapy failure and allergic reactions
during anti-TNFα antibody application [1, 5].
The IDKmonitor® Infliximab total ADA ELISA for the detection of total antibodies
against infliximab (e.g. REMICADE®) measures free and bound antibodies against
infliximab. This assay allows a reliable determination of ADA even in the presence of
infliximab; therefore it is ideal for therapy monitoring when a measurable infliximab
concentration is expected, for example shortly after the last infusion. In combination
with the drug level determination, the IDKmonitor® Infliximab total ADA ELISA is an
opportunity for the treating physician to monitor and optimise the therapy early on.